Skip to content Skip to footer
Subscribe Now
INSIGHTS+

EMA Marketing Authorization of New Drugs in September 2025  

Shots:  The EMA’s CHMP has granted approvals to 5 Biologics and 5 new chemical entities in September 2025, leading to treatments for patients and advances in the healthcare industry    The major highlighted drug, Merck’s Enflonsia, has Adopted Positive Opinion for RSV Prevention in Infants    PharmaShots has compiled a list of 9 drugs that have been…
October 21, 2025

Read more

New Drug Designations: July 2025
INSIGHTS+

New Drug Designations: July 2025

Shots:       PharmaShots’ Designation Report offers a concise overview of the latest drug and device designations granted by major regulatory authorities, including the FDA, EMA, MHLW, Health Canada, and NMPA.    The July 2025 edition covers designations awarded to 47 drugs and 3 medical devices, comprising 23 small molecules, 9 biologics, 8 cell and gene therapies, and…
August 26, 2025

Read more

INSIGHTS+

EMA Marketing Authorization of New Drugs in July 2025  

Shots:  The EMA’s CHMP has granted positive opinions and approvals to 3 Biologics and 10 new chemical entities in July 2025, leading to treatments for patients and advances in the healthcare industry   The major highlighted drug was Roche’s Itovebi Secures the EC’s Approval for PIK3CA-mutated Breast Cancer    PharmaShots has compiled a list of 13 drugs…
August 19, 2025

Read more

A Complete Account of FDA Approvals in 2024
INSIGHTS+

A Complete Account of FDA Approvals in 2024

Shots: In 2024, around 50 new drugs were approved by the US FDA across several indications PharmaShots, in an enlightening report, brings a summarized analysis of the approved drugs. The most explored section remains Oncology, Hematology, Dermatology, and Cardiology For the complete report with analysis, reach out to us at  connect@pharmashots.com   While you embraced the new…
February 5, 2025

Read more

Load more